Dodging Patent Perils in Collaborations

Research collaborations often form the bedrock of truly great science. Scientific alliances can also help businesses commercialize their basic research or reveal the next blockbuster drug. In recent years, economic and competitive pressures have encouraged research collaborations between universities and industry, and between small biotech companies and Big Pharma. While these associations frequently prove to be beneficial for all parties, research collaborations can sometimes trap the unwary, c

Written byPhillip Jones
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Research collaborations often form the bedrock of truly great science. Scientific alliances can also help businesses commercialize their basic research or reveal the next blockbuster drug. In recent years, economic and competitive pressures have encouraged research collaborations between universities and industry, and between small biotech companies and Big Pharma. While these associations frequently prove to be beneficial for all parties, research collaborations can sometimes trap the unwary, creating legal entanglements and endangering intellectual property rights. Recent US court decisions on such cases, as well as pending legislation, may affect research relationships in 2005 and beyond.

One of the most common reasons for a soured research relationship is a patent dispute. In some cases, organizations have convinced courts to include one of their inventors on a patent solely owned by a former collaborator. "This would be the legal equivalent of open warfare," says David J. Aston, a partner with the Palo ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies